MedPath

Pegvisomant

Generic Name
Pegvisomant
Brand Names
Somavert
Drug Type
Biotech
CAS Number
218620-50-9
Unique Ingredient Identifier
N824AOU5XV

Overview

Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.

Background

Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.

Indication

Pegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly.

Associated Conditions

  • Acromegaly

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2022/07/22
Phase 2
Recruiting
2021/11/23
N/A
Recruiting
2019/03/20
Phase 3
Active, not recruiting
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
2017/07/21
N/A
Completed
2016/11/02
Phase 3
Completed
2016/01/29
Phase 4
UNKNOWN
2015/07/16
Not Applicable
Completed
2013/12/30
Phase 2
Completed
2013/07/09
Phase 1
Completed
2013/03/05
Not Applicable
UNKNOWN

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.
© Copyright 2025. All Rights Reserved by MedPath